Blackston Financial Advisory Group’s ELITE PHARMACEUTICAL ELI Stock Holding History

Blackston Financial Advisory Group’s Portfolio ELI Stock Details ELI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-577,605	Closed	-$21K	–	93
2022 Q3	$21K	Hold	577,605	–	–	0.01%	86
2022 Q2	$25K	Buy	577,605 +238,290	+70%	+$10.3K	0.02%	93
2022 Q1	$15K	Sell	339,315 -193,290	-36%	-$8.54K	0.01%	82
2021 Q4	$18K	Buy	+532,605	New	+$18K	0.01%	88

Blackston Financial Advisory Group's ELI Position: Q4 2022 in Review

Blackston Financial Advisory Group sold out of ELITE PHARMACEUTICAL (ELI) in Q4 2022, closing a stake of 577,605 shares — an estimated $21K sold.

Blackston Financial Advisory Group first reported a position in ELI in Q4 2021 and held it in 4 quarters. The position peaked at $25K in Q2 2022. 0 funds tracked by Wall St. Rank hold ELI as of Q4 2022.

Blackston Financial Advisory Group reported no remaining ELITE PHARMACEUTICAL position as of Q4 2022 after selling out during the quarter.
Blackston Financial Advisory Group sold 577,605 ELITE PHARMACEUTICAL shares in Q4 2022, an estimated $21K.
Blackston Financial Advisory Group first reported a position in ELITE PHARMACEUTICAL in Q4 2021 and held it in 4 quarters.
Blackston Financial Advisory Group's ELITE PHARMACEUTICAL position peaked at $25K in Q2 2022.
0 funds tracked by Wall St. Rank held ELITE PHARMACEUTICAL as of Q4 2022.

Based on Blackston Financial Advisory Group's 13F filing for Q4 2022, filed 10 Feb 2023.